The relationships among psychiatric medications, eating behaviors, and weight

Karen M. Davison *

Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Canada

A R T I C L E   I N F O

Article history:
Received 8 July 2012
Received in revised form 21 November 2012
Accepted 15 January 2013
Available online 9 February 2013

Keywords:
Psychiatric medications
 Eating behaviors
 Eating attitudes
 Cognitive dietary restraint
 Disinhibition
 Weight

A B S T R A C T

To help address gaps in information about the links that exist between psychiatric medications and weight changes, an investigation of relationships among select psychotropic agents (i.e., mood stabilizers, antipsychotics, and second-generation antipsychotics (SGAs)), eating behaviors, and weight was conducted. Data from a cross-sectional study of food habits in 97 individuals with mood disorders was used. Variables measured included use of psychotropic agents, measures of cognitive dietary restraint and disinhibition from the Three Factor Eating Behavior Questionnaire (TFEQ), psychiatric functioning, reported weight gain and measured BMI. The TFEQ measures were compared to population norms. Bivariate and multivariate analyses examined the relationships among the psychotropic agents, eating behaviors, and weight. Indicators of cognitive dietary restraint and disinhibition were higher than population norms (p's < 0.05 to 0.0001). Depression was associated with restraint (rho = 0.21, p < 0.05). BMI was associated with disinhibition (p < 0.05); antidepressant use appeared to moderate weight for those taking SGAs and mood stabilizers (p < 0.05). Exploration of the interacting mechanisms of psychotropic agents and attention to eating attitudes and behaviors of individuals taking psychiatric medications might lessen pharmaceutical-induced weight gain. Prospective research on large samples that can make comparisons to those who are untreated is needed.

© 2013 Elsevier Ltd. All rights reserved.

1. Introduction

Weight gain is often associated with the use of mood stabilizers, antipsychotics, and antidepressants (Allison et al., 1999; Parsons et al., 2009; Vanina et al., 2002) which can lead to issues such as metabolic syndrome, cardiovascular disease, medication non-compliance, and relapse risk (Archie et al., 2007). The weight gain experienced while taking psychiatric medications may be due to hyperphagia from lack of satiation (Costa et al., 2001), altered energy homeostasis, and/or endocrine disturbances (Esen-Danaci, Sarandol, Taneli, Yurtsever, & Ozlen, 2008).

Dietary restraint, the intention to restrict food intake to control body weight, and disinhibition or the tendency to overeat in the presence of disinhibiting stimuli (e.g., palatable foods, emotional stress) (Stunkard & Messick, 1988), have been implicated as determinants of weight gain. Dietary disinhibition is positively associated with weight (Hainer et al., 2006; Hays et al., 2002; Lindroos et al., 1997), but the association between dietary restraint and weight remains unclear (Hainer et al., 2006; Hays et al., 2002; Lauzon-Guillain et al., 2006; Lowe et al., 2006) possibly due to interaction effects of restraint and disinhibition (Foster et al., 1998; Hays et al., 2002; Lawson et al., 1995; Williamson et al., 1995).

There has been little investigation of relationships that may exist among the use of psychiatric medications, dietary restraint, disinhibition, and weight. One study reported higher dietary restraint scores in 29 people with schizophrenia who were treated with second generation antipsychotics (SGAs) compared with controls, and found that dietary restraint, as measured by the Three-Factor Eating Questionnaire (TFEQ), correlated positively with disinhibition and BMI (Knolle-Veenjjer, Huth, Ferstl, Aldenhoff, & Hinze-Selch, 2008). Another study examined the TFEQ and the Dutch Eating Behavior Questionnaire (DEBQ) in 93 individuals treated with SGAs, 27 treated with conventional neuroleptics and 33 untreated patients (Sentissi et al., 2009) and found that mean BMI varied significantly among the three groups: DEBQ external eating factor was significantly higher in people treated with SGAs compared to conventional neuroleptics (Sentissi et al., 2009). The TFEQ disinhibition (p = 0.003) and hunger scores (p = 0.017) increased according to BMI.

Investigation of motivators of eating, weight status and the use of different psychiatric medications could help further the understanding of mechanisms of weight gain that often occurs with these drugs. In a study that characterized food intakes of adults with mood disorders, significantly higher intakes of fatty,
sugary, and salty foods were found when compared to population norms (Davison & Kaplan, 2012a, 2012b). Part of this research included collecting data on types of psychiatric medications, dietary restraint, disinhibition, and weight which enabled analysis of the relationships among these variables.

2. Materials and methods

2.1. Sample

The sample was drawn from a survey on food habits and has been detailed elsewhere (Davison & Kaplan, 2012a, 2012b). The study’s protocol was approved by the University of Calgary’s Conjoint Health Research Ethics Board. A clinical interviewer administered the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID) (First, Spitzer, Gibbon, & Williams, 2001), Global Assessment of Functioning (GAF) scale (Jones, Thornicroft, Colley, & Dunn, 1995), Hamilton Depression (Ham-D) scale (Hamilton, 1960), and Young Mania Rating Scale (YMRS) (Young, Biggs, Zierler, & Meyer, 1978).

2.2. Eating behavior and weight measurements

A trained registered dietitian asked questions from the TFEQ (Stunkard & Messick, 1985). To allow for direct comparisons to the British Columbia Nutrition Survey (BCNS) or regional “population norms” (British Columbia Ministry of Health Services, 2004), five items from the restraint subscale and four items from the disinhibition subscale with the highest item-total correlations to each of the subscale scores were selected for inclusion. Other data collected included age of onset of psychiatric condition, types of medications taken, reported weight changes after starting psychiatric medication, as well as sociodemographic, weight, and height information based on standard protocols (British Columbia Ministry of Health Services, 2004).

2.3. Data analysis

Descriptive analyses included using binomial tests of two proportions, as well as parametric and non-parametric statistics where applicable. Three multiple regression models were used to examine the relationships among selected sociodemographic and clinical variables, restraint, disinhibition, and BMI. The data were analyzed using the statistical software program Stata 7.0 (Stata Corporation, 2002).

3. Results

3.1. Sample

The response rate was 75% and there were no significant differences between the respondents (n = 97) and those who declined participation and completed a non-response survey (n = 11) based on a variety of health behaviors such as smoking and multivitamin use. The sample would be described as being mainly females (n = 69; 71.1%) with bipolar disorder (59.8%), taking psychiatric medication (87.6%), and having BMIs exceeding 25 (n = 65; 67%). Their educational attainment levels tended to be less than a bachelor’s degree (n = 76; 78.4%) and they had government-defined low income levels (n = 47; 48.5%). Psychological data suggested that the sample was generally high functioning; GAF (62.7 ± 14.7), YMRS (Median = 3; IQR = 1, 5) and Ham-D scores (Median = 9.6, IQR = 1, 31). For those taking mood stabilizers, there was a higher proportion of the sample (35%) who carried excess weight (BMI > 25) when compared to the use of SGAs (18%) and antidepressants (31%) (p<0.05).

3.2. Restraint and disinhibition: prevalence estimates and sociodemographic differences

The proportion answering yes to individual cognitive dietary restraint and disinhibition questions was higher than population norms (p’s < 0.05 to 0.0001), however, only the overall mean disinhibition scores were significantly higher than the BCNS (Table 1). Generally, women were more likely than men to agree with statements reflecting cognitive dietary restraint or disinhibition (range of p<0.05 to 0.0001). However, more males tended to restrict their food intake in a conscious effort to control weight (p<0.05) or were more likely to go on eating binges (p<0.0001). Disinhibition scores negatively correlated with age (rho = −0.28, p<0.05) and there was a positive correlation between restraint scores and income (p<0.05). Those who answered affirmatively to the statement “I do not eat some foods because they make me fat” tended to have higher education (p<0.05).

3.3. Relationships among restraint, disinhibition, and BMI

Ham-D and restraint scores were positively correlated (rho = 0.21, p<0.05). Higher BMI was associated with disinhibition (p<0.05). There tended to be a higher proportion who reported weight changes since starting their psychiatric medications and agreed with dietary restraint and disinhibition statements (p’s < 0.05 to 0.0001). The use of mood stabilizers was associated with excess weight (p<0.05) (Table 1). Disinhibition and BMI were significantly associated with interactive effects among select medications (Fig. 1); Antidepressants appeared to moderate the effects of SGAs and mood stabilizers on BMI (p’s < 0.05). Interaction was also found between SGAs and mood stabilizers in relationship to disinhibition scores (p<0.05).

4. Discussion

In this study, dietary restraint and disinhibition were significantly more prevalent than population norms and were associated with weight gain. While disinhibition was positively correlated with BMI, restraint was associated with depression. Antidepressant use was associated with components of disinhibition and moderated relationships between BMI, SGAs and mood stabilizers. Disinhibition was associated with the interaction of SGAs and mood stabilizers.

The results support different theories about cognitive dietary restraint, disinhibition and weight. The finding that a lower proportion of individuals reported weight gain when some dietary restraint was present support the hypotheses that cognitive dietary restraint contributes to weight suppression (Barr & Rideout, 2009) and may help with weight management. Conversely, high dietary restraint may have serious implications as it can create psychological stress that activates the hypothalamic-pituitary-adrenal axis, increases release of cortisol (Miller & O’Callaghan, 2002), and affects mood stability (McEwen & Stellar, 1993). Prospective investigations could determine if depression can be attributed to altered nutrition and molecular functions or if the psychological effects of restraint, separate from biochemical changes due to diet, affect psychiatric symptoms; it is likely the relationships between food restriction and negative mood state are interactive. Finally, the correlation between BMI and disinhibition scores may lend support to theories regarding the relationships among the neurotransmitters serotonin and histamine with control of appetite (Blouin et al., 2008).

Some of the findings of this study were unexpected and should be interpreted with caution. It was surprising that only mood stabilizers were associated with excess weight and that there were significant interactions among antidepressants, SGAs and mood stabilizers with BMI. While the exact mechanisms of action for antidepressants,
SGAs and mood stabilizers are relatively unknown, the results suggest that certain combinations moderate eating and weight. However, this small, hypothesis-generating, cross-sectional study that did not include measures of hunger and dieting behavior, which could help account for evidence of eating behavior and weight (Savage, Hoffman, & Birch, 2009), presents findings that are speculative.

The main results suggest that associations exist among restraint, disinhibition, weight, and psychiatric medication use and that antidepressants combined with SGAs or mood stabilizers may moderate BMI. Exploration of the interacting mechanisms of antidepressants, SGAs, and mood stabilizers and attention to eating attitudes and behaviors of individuals taking psychiatric medications might lessen pharmaceutical-induced weight gain. However, prospective studies using larger samples and comparisons to those who are untreated are needed.

**Role of funding source**

The Danone Research Institute provided financial support for the conduct of this research project. The funder did not have any role in study design, collection, analysis,
Contributors
This work is based on the author’s doctoral work at the Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Calgary, Alberta.

Conflict of interest
The author has no conflicts of interest to declare.

Acknowledgements
Thank you to Dr. Bonnie J. Kaplan for her insights on the development of the manuscript. Gratitude is also extended to the funding source for this study, the Danone Research Institute and the Mood Disorders Association of British Columbia for providing support staff, office space and assistance with the recruitment.

References


Stata Corporation (2002). *Stata statistics/data analysis.* (7.0). College Station, TX: Stata Corporation.


